Literature DB >> 9228502

No effects of human relaxin on the active and passive biomechanical properties of isolated cervical specimens from nonpregnant women.

L K Petersen1, I Vogel, H Oxlund, A Forman, N Uldbjerg.   

Abstract

OBJECTIVE: To evaluate the effect of human relaxin (hRLX-2) on the active and passive biomechanical properties of cervical tissue in vitro. MATERIAL: Cervical samples were obtained from the middle part of the cervix in 22 nonpregnant women undergoing hysterectomy.
METHODS: The effect of hRLX-2 (10(-7) M) on the active biomechanical properties was studied on vasopressin (10(-8) M) induced smooth muscle contractions in an organ bath model. The effect on the passive biomechanical properties were studied after incubation of the strips for 48 h with hRLX-2 (10(-8) M and 10(-9) M). Subsequently, the specimens were stretched in a material testing machine until they broke. The load applied and the elongation were simultaneously recorded and the results translated into stress-strain curves.
RESULTS: hRLX-2 did not influence the vasopressin-induced contractility of cervical strips from nonpregnant women in this study. No synergistic effect of progesterone could be demonstrated. The passive biomechanical properties (tensile strength, extensibility, stiffness of failure energy) did not change significantly after relaxin incubation. The results obtained in vitro do not suggest an important physiological effect of relaxin on the human nonpregnant cervix.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228502     DOI: 10.1016/s0301-2115(97)02732-2

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

1.  Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.

Authors:  Petar Arsenijevic; Marko Milosevic; Aleksandar Zivanovic; Biljana Milicic; Branislav Jeremic; Nenad Filipovic; Zoran Protrka; Petar Todorovic; Slobodan Arsenijevic
Journal:  Trials       Date:  2015-10-28       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.